Appclon rises 7.12% amid immune checkpoint inhibitor theme uptrend

On the 11th, the immuno-oncology theme rose by 3.11% compared to the previous day, showing strength, while Appclon, a related stock attracting attention, surged by 7.12% compared to the previous day. Appclon is known as the only domestic bio new drug development specialist among listed companies.

[Graph] Price Fluctuations of Major Stocks in the Immuno-Oncology Theme

According to provisional data compiled at 11:01, foreign investors and institutions are net buying 3,400 shares and 3,000 shares respectively of Appclon.

[Table] Net Trading Volume of Foreign Investors and Institutions (Unit: 10,000 shares)

According to the analysis by Thinkpool Robo Algorithm RASSI, Appclon's quant financial score is 10.61 points, with higher growth and stability scores than the average of other stocks related to immuno-oncology, ranking 11th within the theme. This indicates that compared to other stocks in the theme, Appclon's sales and net profit growth rates are relatively fast, and its ability to respond to changes in domestic and international economic environments is also favorable.

[Table] Top Stocks by Financial Score within the Theme

※ The quant financial score is the result of the Robo Algorithm analyzing each company's sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist Thinkpool.

This content was produced with the assistance of AI translation services.